637022-55-0

Basic information

• Product Name: Piperazine, 1-(4-chloro-3-methylphenyl)-
• CAS NO: 637022-55-0
• Molecular Formula: C11H15ClN2
• Molecular Weight: 210.706
• Mol File: 637022-55-0.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: Piperazine, 1-(4-chloro-3-methylphenyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: Piperazine, 1-(4-chloro-3-methylphenyl)-(637022-55-0)
• EPA Substance Registry System: Piperazine, 1-(4-chloro-3-methylphenyl)-(637022-55-0)

Safety Data

• Hazardous Substances Data: 637022-55-0(Hazardous Substances Data)

Upstream product

• 821-48-7 bis-(2-chloroethyl)amine hydrochloride 
• 7149-75-9 3-methyl-4-chloroaniline 

Relevant articles and documents

Optimization of 5-substituted thiazolyl ureas and 6-substituted imidazopyridines as potential HIV-1 latency reversing agents

A persistent latent reservoir of virus in CD4+ T cells is a major barrier to cure HIV. Activating viral transcription in latently infected cells using small molecules is one strategy being explored to eliminate latency. We previously described the use of a FlpIn.FM HEK293 cellular assay to identify and then optimize the 2-acylaminothiazole class to exhibit modest activation of HIV gene expression. Here, we implement two strategies to further improve the activation of viral gene expression and physicochemical properties of this class. Firstly, we explored rigidification of the central oxy-carbon linker with a variety of saturated heterocycles, and secondly, investigated bioisosteric replacement of the 2-acylaminothiazole moiety. The optimization process afforded lead compounds (74 and 91) from the 2-piperazinyl thiazolyl urea and the imidazopyridine class. The lead compounds from each class demonstrate potent activation of HIV gene expression in the FlpIn.FM HEK293 cellular assay (both with LTR EC50s of 80 nM) and in the Jurkat Latency 10.6 cell model (LTR EC50 220 and 320 nM respectively), but consequently activate gene expression non-specifically in the FlpIn.FM HEK293 cellular assay (CMV EC50 70 and 270 nM respectively) manifesting in cellular cytotoxicity. The lead compounds have potential for further development as novel latency reversing agents.

1-ARYL-4-SUBSTITUTED PIPERAZINES DERIVATIVES FOR USE AS CCR1 ANTAGONISTS FOR THE TREATMENT OF INFLAMMATION AND IMMUNE DISORDERS

Compounds are provided that act as potent antagonists of the CCR1 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR1. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.